SBP-101 Market

“SBP-101 Market Size, Forecast, and Emerging Insight – 2032” report provides comprehensive insights about SBP-101 for Pancreatic Cancer in the seven major markets. A detailed picture of the SBP-101 for pancreatic cancer in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 –2032 is provided in this report along with a detailed description of the SBP-101 for pancreatic cancer. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the SBP-101 market forecast analysis for pancreatic cancer in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in pancreatic cancer.

Drug Summary

SBP-101 is a proprietary polyamine analog designed to induce polyamine metabolic inhibition (PMI) by exploiting an observed high affinity of the compound for pancreatic ductal adenocarcinoma and other tumors. Laboratory studies suggest the primary mechanism of action of SBP-101 is driven by its enhanced uptake in pancreatic cancer cells and, potentially, other cancer cell types, resulting in disruption of normal polyamine metabolism. SBP-101 is also taken up preferentially by the exocrine pancreas, the liver, and kidneys. Importantly, pancreatic islet cells, which secrete insulin and are structurally and functionally dissimilar to acinar cells, are not impacted by SBP-101.

The molecule has shown signals of tumor growth inhibition in clinical studies of the US and Australian metastatic pancreatic cancer patients, demonstrating a median overall survival (OS) of 14.6 months which is final, and an objective response rate (ORR) of 48%, both exceeding what is seen typically with the standard of care of gemcitabine + nab-paclitaxel suggesting potential complementary activity with the existing FDA-approved standard chemotherapy regimen. In data evaluated from clinical studies, SBP-101 has not shown exacerbation of bone marrow suppression and peripheral neuropathy, which can be chemotherapy-related adverse events.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the SBP-101 description, mechanism of action, dosage and administration, research and development activities in pancreatic cancer.
• Elaborated details on SBP-101 regulatory milestones and other development activities have been provided in this report.
• The report also highlights the SBP-101 research and development activities in pancreatic cancer across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around SBP-101.
• The report contains forecasted sales of for pancreatic cancer till 2032.
• Comprehensive coverage of the late-stage emerging therapies for pancreatic cancer.
• The report also features the SWOT analysis with analyst views for SBP-101 in pancreatic cancer.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

SBP-101 Analytical Perspective by DelveInsight

In-depth SBP-101 Market Assessment

This report provides a detailed market assessment of SBP-101 for pancreatic cancer in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data of SBP-101.

SBP-101 Clinical Assessment

The report provides the clinical trials information of SBP-101 for pancreatic cancer covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights 

• In the coming years, the market scenario for pancreatic cancer is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.  
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence SBP-101 dominance.
• Other emerging products for pancreatic cancer are expected to give tough market competition to SBP-101 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of SBP-101 in pancreatic cancer.
• Our in-depth analysis of the forecasted sales data of SBP-101 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the SBP-101 in pancreatic cancer.

Key Questions

• What is the product type, route of administration and mechanism of action of SBP-101?
• What is the clinical trial status of the study related to SBP-101 in pancreatic cancer and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the SBP-101 development?
• What are the key designations that have been granted to SBP-101 for pancreatic cancer?
• What is the forecasted market scenario of SBP-101 for pancreatic cancer?
• What are the forecasted sales of SBP-101 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan? 
• What are the other emerging products available and how are these giving competition to SBP-101 for pancreatic cancer?
• Which are the late-stage emerging therapies under development for the treatment of pancreatic cancer?